Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prime-2-CoV_Beta Booster in Healthy Adults
NCT05389319Phase 1Active, not recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRIME-2-CoV_Beta in coronavirus disease 2019 (COVID-19) (7 cohorts), sponsored by University Hospital Tübingen. Primary endpoints: Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), Proportion of participants with solicited local adverse events and 2 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
PRIME-2-CoV_Beta
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05389319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389319.